Literature DB >> 8563098

Autonomic nervous disorder in motor neuron disease: a study of advanced stage patients.

K Sato1, R Namba, T Hayabara, K Kashihara, K Morimoto.   

Abstract

Autonomic functions were studied in 10 respiratory-support patients with motor neuron disease (MND) at its most advanced stage by means of hemodynamic function tests. The mean duration of disease was 83.4 months (SD 28.0, range 50-140 months). All the patients in this study had lost their ability to breathe spontaneously and were ventilated by respirator. Hemodynamic function tests were performed in 8 out of 10 patients. These patients showed exaggerated sympathetic vasomotor reflexes, increased reflex hypertension and tachycardia in response to the cold pressor test and increased response to administration of adrenaline. However, the responses to both the Aschner eyeball pressure test and injection of atropine were normal, indicating normal parasympathetic nervous system function. Plasma and urine levels of norepinephrine, epinephrine and their metabolites were almost normal in all 10 patients, as were serum dopamine-beta-hydroxylase levels. In patients with the most advanced stage of MND, hyperfunction of the adrenergic sympathetic nervous system was observed, and this was considered to be a symptom characteristic of MND.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563098     DOI: 10.2169/internalmedicine.34.972

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

Review 1.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

2.  Colostomy as a definitive treatment in an ALS patient with acute colonic Pseudo-obstruction refractory to medical management, a case report.

Authors:  Guanghao Liu; Jennifer Hrabe; Rolando Sanchez
Journal:  BMC Neurol       Date:  2022-09-22       Impact factor: 2.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.